SE515285C2 - Oralt vaccin mot diarré - Google Patents

Oralt vaccin mot diarré

Info

Publication number
SE515285C2
SE515285C2 SE9804415A SE9804415A SE515285C2 SE 515285 C2 SE515285 C2 SE 515285C2 SE 9804415 A SE9804415 A SE 9804415A SE 9804415 A SE9804415 A SE 9804415A SE 515285 C2 SE515285 C2 SE 515285C2
Authority
SE
Sweden
Prior art keywords
cfa
defined amount
vaccine
etec
ctb
Prior art date
Application number
SE9804415A
Other languages
English (en)
Swedish (sv)
Other versions
SE9804415D0 (sv
SE9804415L (sv
Inventor
Nils Carlin
Per Askeloef
Ulf Bjare
Original Assignee
Sbl Vaccin Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbl Vaccin Ab filed Critical Sbl Vaccin Ab
Priority to SE9804415A priority Critical patent/SE515285C2/sv
Publication of SE9804415D0 publication Critical patent/SE9804415D0/xx
Priority to YU41701A priority patent/YU41701A/sh
Priority to KR1020017007484A priority patent/KR20010101233A/ko
Priority to PL348257A priority patent/PL198438B1/pl
Priority to CA002352309A priority patent/CA2352309A1/en
Priority to PCT/SE1999/002306 priority patent/WO2000037106A1/en
Priority to CN99814553A priority patent/CN1330552A/zh
Priority to CZ20011947A priority patent/CZ20011947A3/cs
Priority to AU30889/00A priority patent/AU778223B2/en
Priority to IDW00200101304A priority patent/ID29857A/id
Priority to EP04010662A priority patent/EP1444987A3/en
Priority to TR2001/01542T priority patent/TR200101542T2/xx
Priority to MXPA01006200A priority patent/MXPA01006200A/es
Priority to HU0104552A priority patent/HUP0104552A3/hu
Priority to APAP/P/2001/002174A priority patent/AP1426A/en
Priority to JP2000589216A priority patent/JP2002532562A/ja
Priority to NZ527559A priority patent/NZ527559A/en
Priority to EP99964847A priority patent/EP1140159A1/en
Priority to IL14380899A priority patent/IL143808A0/xx
Priority to OA1200100151A priority patent/OA11729A/en
Priority to EEP200100309A priority patent/EE200100309A/xx
Priority to BR9916278-4A priority patent/BR9916278A/pt
Publication of SE9804415L publication Critical patent/SE9804415L/
Priority to ZA200104362A priority patent/ZA200104362B/en
Priority to HR20010433A priority patent/HRP20010433A2/hr
Priority to NO20012889A priority patent/NO20012889D0/no
Priority to IS5967A priority patent/IS5967A/is
Publication of SE515285C2 publication Critical patent/SE515285C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SE9804415A 1998-12-18 1998-12-18 Oralt vaccin mot diarré SE515285C2 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE9804415A SE515285C2 (sv) 1998-12-18 1998-12-18 Oralt vaccin mot diarré
BR9916278-4A BR9916278A (pt) 1998-12-18 1999-12-09 Composição de vacina oral contra a diarréia e vacina
MXPA01006200A MXPA01006200A (es) 1998-12-18 1999-12-09 Vacuna oral contra la diarrea.
APAP/P/2001/002174A AP1426A (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea.
PL348257A PL198438B1 (pl) 1998-12-18 1999-12-09 Doustna kompozycja szczepionki przeciwko biegunce
CA002352309A CA2352309A1 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
PCT/SE1999/002306 WO2000037106A1 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
CN99814553A CN1330552A (zh) 1998-12-18 1999-12-09 抗腹泻的口服疫苗
CZ20011947A CZ20011947A3 (cs) 1998-12-18 1999-12-09 Orální vakcína proti diarea
AU30889/00A AU778223B2 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
IDW00200101304A ID29857A (id) 1998-12-18 1999-12-09 Vaksin oral terhadap diare
EP04010662A EP1444987A3 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
TR2001/01542T TR200101542T2 (tr) 1998-12-18 1999-12-09 İshale karşı oral aşı
YU41701A YU41701A (sh) 1998-12-18 1999-12-09 Oralna vakcina protiv dijareje
HU0104552A HUP0104552A3 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
KR1020017007484A KR20010101233A (ko) 1998-12-18 1999-12-09 설사 예방용 경구용 백신
JP2000589216A JP2002532562A (ja) 1998-12-18 1999-12-09 下痢に対する経口ワクチン
NZ527559A NZ527559A (en) 1998-12-18 1999-12-09 Oral vaccine against enterotoxigenic E. coli comprising at least three different types of colonisation factor antigens on killed and modified E coli and the B-subunit of cholera toxin
EP99964847A EP1140159A1 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
IL14380899A IL143808A0 (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea
OA1200100151A OA11729A (en) 1998-12-18 1999-12-09 Oral vaccine against diarrhea.
EEP200100309A EE200100309A (et) 1998-12-18 1999-12-09 Suukaudne vaktsiinikompositsioon diarröad põhjustava enterotoksigeense E. coli vastu
ZA200104362A ZA200104362B (en) 1998-12-18 2001-05-28 Oral vaccine against diarrhea.
HR20010433A HRP20010433A2 (en) 1998-12-18 2001-06-08 Oral vaccine against diarrhea
NO20012889A NO20012889D0 (no) 1998-12-18 2001-06-12 Oral vaksine mot diar±
IS5967A IS5967A (is) 1998-12-18 2001-06-13 Bóluefni til inntöku gegn niðurgangi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804415A SE515285C2 (sv) 1998-12-18 1998-12-18 Oralt vaccin mot diarré

Publications (3)

Publication Number Publication Date
SE9804415D0 SE9804415D0 (sv) 1998-12-18
SE9804415L SE9804415L (sv) 2000-06-19
SE515285C2 true SE515285C2 (sv) 2001-07-09

Family

ID=20413742

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804415A SE515285C2 (sv) 1998-12-18 1998-12-18 Oralt vaccin mot diarré

Country Status (25)

Country Link
EP (2) EP1140159A1 (ja)
JP (1) JP2002532562A (ja)
KR (1) KR20010101233A (ja)
CN (1) CN1330552A (ja)
AP (1) AP1426A (ja)
AU (1) AU778223B2 (ja)
BR (1) BR9916278A (ja)
CA (1) CA2352309A1 (ja)
CZ (1) CZ20011947A3 (ja)
EE (1) EE200100309A (ja)
HR (1) HRP20010433A2 (ja)
HU (1) HUP0104552A3 (ja)
ID (1) ID29857A (ja)
IL (1) IL143808A0 (ja)
IS (1) IS5967A (ja)
MX (1) MXPA01006200A (ja)
NO (1) NO20012889D0 (ja)
NZ (1) NZ527559A (ja)
OA (1) OA11729A (ja)
PL (1) PL198438B1 (ja)
SE (1) SE515285C2 (ja)
TR (1) TR200101542T2 (ja)
WO (1) WO2000037106A1 (ja)
YU (1) YU41701A (ja)
ZA (1) ZA200104362B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372708B1 (en) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
CN101730737B (zh) * 2007-04-24 2016-06-01 赛尔戴克斯治疗公司 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性
DK2750701T3 (en) * 2011-09-12 2016-01-11 Scandinavian Biopharma Holding Ab PROCEDURE FOR INCREASING ETEC-CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND THEREFORE AVAILABLE PRODUCTS
BR112014005601B1 (pt) * 2011-09-12 2020-09-29 Scandinavian Biopharma Holding Ab Vacina oral para a imunização contra a diarréia induzida pela etec
RU2753410C2 (ru) * 2020-01-14 2021-08-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ получения анатоксин-вакцины против эшерихиоза животных

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100556D0 (sv) * 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans

Also Published As

Publication number Publication date
HUP0104552A3 (en) 2002-08-28
TR200101542T2 (tr) 2001-10-22
CA2352309A1 (en) 2000-06-29
EP1140159A1 (en) 2001-10-10
AU778223B2 (en) 2004-11-25
SE9804415D0 (sv) 1998-12-18
EP1444987A2 (en) 2004-08-11
PL348257A1 (en) 2002-05-20
NO20012889L (no) 2001-06-12
SE9804415L (sv) 2000-06-19
ZA200104362B (en) 2002-01-14
JP2002532562A (ja) 2002-10-02
CN1330552A (zh) 2002-01-09
HRP20010433A2 (en) 2002-06-30
WO2000037106A1 (en) 2000-06-29
AP1426A (en) 2005-06-06
PL198438B1 (pl) 2008-06-30
EP1444987A3 (en) 2005-12-21
HUP0104552A2 (hu) 2002-04-29
IL143808A0 (en) 2002-04-21
NZ527559A (en) 2005-01-28
NO20012889D0 (no) 2001-06-12
ID29857A (id) 2001-10-18
BR9916278A (pt) 2001-09-04
OA11729A (en) 2005-05-12
KR20010101233A (ko) 2001-11-14
EE200100309A (et) 2002-08-15
CZ20011947A3 (cs) 2001-12-12
YU41701A (sh) 2005-07-19
IS5967A (is) 2001-06-13
MXPA01006200A (es) 2002-04-17
AU3088900A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
Hill et al. Oral cholera vaccines: use in clinical practice
Wennerås et al. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world
Cohen et al. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population
Darsley et al. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease
Tozzi et al. Diagnosis and management of pertussis
Jertborn et al. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine
Qadri et al. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age
Simanjuntak et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children
Qadri et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants
Savarino et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants
Wennerås et al. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine
Taylor et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru
Qadri et al. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6–17 months of age: dosing studies in different age groups
Seo et al. Preclinical characterization of immunogenicity and efficacy against diarrhea from MecVax, a multivalent enterotoxigenic E. coli vaccine candidate
Sack et al. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers
Coster et al. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli
LEVINE et al. Pediatric diarrhea: the challenge of prevention
Tamura et al. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit
Jertborn et al. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine
SE515285C2 (sv) Oralt vaccin mot diarré
Ruuskanen et al. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults
Taylor et al. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama
Blanden et al. Effects of thymus‐independent (B) cells and the H‐2 gene complex on antiviral function of immune thymus‐derived (T) cells
Levine et al. Texas Star-SR: attenuated Vibrio cholerae oral vaccine candidate
Kobayashi et al. Tetravalent rhesus rotavirus vaccine in young infants

Legal Events

Date Code Title Description
NUG Patent has lapsed